Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

First Posted Date
2024-02-07
Last Posted Date
2024-05-08
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT06245889
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

First Posted Date
2024-02-07
Last Posted Date
2024-11-21
Lead Sponsor
Eikon Therapeutics
Target Recruit Count
70
Registration Number
NCT06246110
Locations
🇺🇸

Tennessee Cancer Specialists, Knoxville, Tennessee, United States

🇺🇸

Southern Cancer Care, Daphne, Alabama, United States

🇺🇸

Ironwood Cancer and Research Center, Chandler, Arizona, United States

and more 31 locations

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

First Posted Date
2024-02-05
Last Posted Date
2024-04-02
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
48
Registration Number
NCT06241235
Locations
🇨🇳

Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2024-02-01
Last Posted Date
2024-11-28
Lead Sponsor
AbbVie
Target Recruit Count
840
Registration Number
NCT06236438
Locations
🇺🇸

University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States

🇺🇸

Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States

🇺🇸

Bond Clinic /ID# 262611, Winter Haven, Florida, United States

and more 25 locations

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

First Posted Date
2024-02-01
Last Posted Date
2024-02-01
Lead Sponsor
Xiang Lu
Target Recruit Count
30
Registration Number
NCT06235918
Locations
🇨🇳

Tongji Hospital, Wuhan, Hubei, China

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

First Posted Date
2024-01-31
Last Posted Date
2024-01-31
Lead Sponsor
Wang Ouchen
Target Recruit Count
154
Registration Number
NCT06234137
Locations
🇨🇳

the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

First Posted Date
2024-01-30
Last Posted Date
2024-12-10
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
216
Registration Number
NCT06230224
Locations
🇨🇳

Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan

🇹🇷

VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey

🇦🇺

Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 54 locations

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

First Posted Date
2024-01-26
Last Posted Date
2024-03-19
Lead Sponsor
RemeGen Co., Ltd.
Target Recruit Count
120
Registration Number
NCT06227117
Locations
🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

and more 2 locations

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

First Posted Date
2024-01-19
Last Posted Date
2024-05-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
378
Registration Number
NCT06212752
Locations
🇯🇵

Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan

🇯🇵

Fujita Health University ( Site 4406), Toyoake, Aichi, Japan

🇯🇵

Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan

and more 15 locations

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

First Posted Date
2024-01-18
Last Posted Date
2024-01-18
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
520
Registration Number
NCT06211023
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy